[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 7 sources · 2 days · First seen · Last updated

Celltrion pharmaceutical market expansion

Overview

Celltrion has initiated efforts to expand its global pharmaceutical footprint through strategic partnerships and market penetration. The company announced its participation in the CPHI exhibition in Milan to seek new drug pipeline partnerships in areas such as oncology, obesity, and autoimmune diseases, while also aiming to expand its Contract Development and Manufacturing Organization (CDMO) services.

Following these strategic moves, Celltrion has successfully increased its biosimilar market share across several European nations. The company secured significant government tenders in Norway, Finland, and the Netherlands, particularly for its autoimmune disease treatment, Aptozma. Additionally, products such as Omlyclo and Osenvelt have secured sole supply rights or tenders in Denmark and Norway, driven by the company’s established direct sales networks.

Entities

Celltrion · Yuhan Corporation · Daewon Pharmaceutical · Omlyclo · Humedix

Timeline

  1. [BUSINESS] 2 sources
    Celltrion expands European biosimilar market share through new tenders

    Celltrion is expanding its European biosimilar market share, securing major tenders for Aptozma, Omlyclo, and Osenvelt in Norway, Denmark, Finland, and the Netherlands.

  2. [BUSINESS] 6 sources
    Celltrion to seek new drug and CDMO partnerships at CPHI Milan

    Celltrion seeks new drug and CDMO partnerships at the CPHI exhibition in Milan, while other Korean firms report expanded distribution and resumed drug supplies.

Sources

biotimes.co.kr · biz.heraldcorp.com · gyominilbo.com · kormedi.com · sateconomy.co.kr · techholic.co.kr · thebionews.net